A Randomized Trial of Genotype-Guided Dosing of Warfarin

  title={A Randomized Trial of Genotype-Guided Dosing of Warfarin},
  author={M. Pirmohamed and G. Burnside and N. Eriksson},

Topics from this paper

The influence of age, vitamin K and genetics on anticoagulation outcomes in adults and children
................................................................................................................ i DECLARATION OF ORIGINALITYExpand
Current status of personalized medicine based on pharmacogenetics in cardiovascular medicine
There is a considerable amount of pharmacogenetic information currently available relevant to cardiovascular therapeutics, but it is not used routinely in most centers and monitoring of the international normalized ratio (INR) followed by careful dose adjustments is essential for individual patients to obtain the desired degree of anticoagulation. Expand
Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland
  • K. Brøsen
  • Medicine
  • Drug metabolism and personalized therapy
  • 2015
The O-demethylation of codeine and tramadol to their respective my-opioid active metabolites, morphine and (+)-O-desmethyltramadol was markedly impaired in CYP2D6 poor metabolizers compared to extensive metabolizers, and this impairs the hypoalgesic effect of the two drugs in the poor metabolizer. Expand
Vitamin K: dietary intake and requirements in different clinical conditions
With the increased incidence of vitamin K-deficient bleeding and weight-loss surgical procedures, healthcare professionals need to monitor vitamin K status in certain patient populations. Expand
Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial
Among Asian adults commencing warfarin therapy, a pharmacogenetic algorithm meets criteria for both non-inferiority and superiority in reducing dose titrations compared with a traditional dosing approach, and performs well in prediction of actual maintenance doses. Expand
Cardiovascular pharmacogenetics: a promise for genomically‐guided therapy and personalized medicine
An overview of the extraordinary scientific progress in the understanding of genetic and genomic basis of CVD as well as the development of relevant genetic biomarkers for this disease is provided. Expand
Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
A review of the evidence to date on the association between cytochrome P450 enzymes and the clinical end points of warfarin and tamoxifen therapy will provide a summary of the utility and the limitations of pharmacogenomics-guided care. Expand
Warfarin Pharmacogenetics Reevaluated:  Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials.
Patient subgroups were identified that obtained the largest pharmacogenetic improvements in warfarin dose accuracy and these subgroups have not been analyzed in clinical trials to date, likely resulting in underestimation of the pharmacogenetics benefit. Expand
Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials.
PG algorithm-guided warfarin anticoagulation is beneficial for the reduction of both major bleeding and thromboembolic events compared with standard dosing strategy and may be prominent in patients with longer follow-up time, or guided by refined PG algorithms. Expand
Research progress in CYP2C9 and VKORC1 gene polymorphism and individualized warfarin therapeutic regimen
The association between the polymorphism of CYP2C9 and VKORC1 and individualized warfarin therapeutic regimen are mainly discussed in this paper. Expand